Bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), has become a cornerstone in oncology treatment worldwide. As patents expire and biosimilar competition intensifies, the global buyer landscape for this critical therapeutic has evolved dramatically. This guide examines the key importers, procurement patterns, and market forces shaping Bevacizumab sourcing across international markets. Understanding Bevacizumab: Clinical Significance and Market Position Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that functions as an anti-angiogenic agent by inhibiting vascular endothelial growth factor. It is indicated for treating several cancers, including metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and cervical cancer. The World Health Organization includes Bevacizumab…